$NKTR News Article - Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
https://marketwirenews.com/news-releases/nekt...56746.html